Erasca Expects Its $947.8 Million Cash Pile To Cover Planned Cancer-Drug Trial Milestones

A July offering strengthened its finances as quarterly research spending rose to $47.2 million from $22.5 million.

Share
Erasca Expects Its $947.8 Million Cash Pile To Cover Planned Cancer-Drug Trial Milestones

Erasca, which is testing experimental medicines for pancreatic and lung cancers, holds $947.8 million in cash and investments and expects that money to cover its planned clinical milestones. Thursday's SEC earnings filing put the balance at September 30, up from $341.8 million at the end of 2025.

July Financing Pays For The Pipeline

Erasca completed a public offering in July that supplied approximately $632.5 million before expenses. Its funding plan includes studies that could support applications for approval in pancreatic and lung cancers.

“We are rapidly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers,” Jonathan E. Lim, Erasca's chairman, CEO and co-founder, said in the earnings release.

Erasca develops medicines aimed at RAS proteins and related signaling pathways that can drive tumors. Its clinical pipeline includes ERAS-0015 and ERAS-4001, alongside an antibody research program called ERAS-12. The company combines its own research with licensed and purchased medicines and controls worldwide development and commercialization rights to its pipeline.

Research Costs Climb

Third-quarter research and development expenses rose to $47.2 million from $22.5 million a year earlier. Erasca attributed the increase primarily to clinical and preclinical studies, discovery research, personnel costs including stock compensation, and outside services and consulting.

Administrative spending reached $12.3 million, compared with $10.1 million a year earlier, chiefly because of personnel costs, including stock compensation, the company said. The quarterly net loss widened to $51.3 million, or $0.15 per share, from $30.6 million, or $0.11 per share.

For the first nine months, Erasca recorded $150 million in expenses for research projects still under development, compared with $9.5 million a year earlier. Its nine-month net loss reached $278.9 million, or $0.87 per share, versus $95.5 million, or $0.34 per share.

Pancreatic And Lung Trials Ahead

ERAS-0015 received Fast Track designation from the FDA in August for metastatic pancreatic cancer. That status can provide more frequent contact with the agency during development; it leaves approval standards unchanged.

Erasca also appointed Charles Fuchs president of research and development and David Chonzi senior vice president of global pharmacovigilance in August.

The company expects preliminary ERAS-4001 results in the second half of 2026, covering safety, tolerability, how the drug behaves in the body and initial evidence of effectiveness. It plans to expand testing of the drug alone and begin combination testing in 2027.

For ERAS-0015, Erasca expects expanded early-stage results from treatment alone and combination testing, including with panitumumab, in the first half of 2027. It also expects to begin a potentially approval-supporting study in previously treated non-small cell lung cancer during that period.

Erasca expects a late-stage trial in first-line pancreatic cancer to start in 2027. Another late-stage trial, for RAS-mutant non-small cell lung cancer, is expected to begin between the second half of 2027 and the first half of 2028.

The next scheduled presentation is at the ENA cancer symposium in Barcelona, November 18–20. Erasca plans to present updated ERAS-0015 results with additional patients and longer follow-up, plus laboratory results for its combination with ERAS-4001.

Sources